Welcome to our dedicated page for CDAK news (Ticker: CDAK), a resource for investors and traders seeking the latest updates and insights on CDAK stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CDAK's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CDAK's position in the market.
Codiak BioSciences (NASDAQ: CDAK) announced significant operational progress in its Q3 2020 financial results, with total revenues reaching $1.0 million, up from $0.2 million in Q3 2019. The company initiated clinical trials for exoIL-12 and exoSTING, with key safety and efficacy data expected by mid-2021. Despite a net loss of $35.3 million, increased R&D expenses of $30.7 million were attributed to clinical trial activities. The recent IPO generated $74.4 million in net proceeds, supporting ongoing development and operational momentum.
Codiak BioSciences (NASDAQ: CDAK) presents preclinical data at the SITC 2020, showcasing its engEx™ Platform's capabilities for engineered exosome therapeutics. Key findings highlight that the exoIL-12 candidate exhibits 15-fold improved retention at injection sites and 100-fold enhanced tumor growth inhibition compared to recombinant IL-12. The candidate's administration resulted in significant infiltration of cytotoxic T-cells and M1 macrophages, indicating enhanced immune activity. Clinical trials for exoIL-12 and exoSTING™ began in September 2020, with preliminary results expected by the end of the year.
Codiak BioSciences has announced its initial public offering (IPO) of 5,500,000 shares at $15.00 per share, aiming for gross proceeds of approximately $82.5 million. The offering will begin trading on the Nasdaq under the symbol CDAK on October 14, 2020, with expected closing on October 16, 2020. Codiak has also granted underwriters a 30-day option for up to 825,000 additional shares. The company is focused on developing exosome-based therapeutics through its proprietary engEx Platform, targeting various diseases including oncology and neurology.